Bruker advances Functional Proteomics 2.0 with timsOmni™ mass spectrometry proteoform analysis for deeper insights into disease biology

Bruker Corporation today announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional proteoforms and PTM-resolved peptide variants.